FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to drugs, and concerns a therapeutic agent for treating hepatitis containing 2-amino-2-[4-3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediole or its pharmaceutically acceptable salt, or hydrate as an active ingredient. Also, disclosed is a method of treating hepatitis by introducing to a patient an effective amount of the therapeutic agent 2-amino-2-[4-3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediole or its pharmaceutically acceptable salt, or hydrate as an active ingredient.
EFFECT: therapeutic agent shows a stronger effect in treating hepatitis as compared to the other analogues.
4 cl, 3 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC MEDICATION FOR INFLAMMATORY INTESTINAL DISEASES WHICH CONTAINS DERIVATIVE OF 2-AMINO-1,3-PROPANDIOL AS ACTIVE INGREDIENT, OR METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES | 2007 |
|
RU2428976C2 |
| EFFECTIVE METHOD OF USING DRUGS AND METHOD FOR PREVENTION OF BY-EFFECTS INTENSITY | 2005 |
|
RU2396982C2 |
| HEPATITIS B VIRUS INHIBITOR (HBV) | 2019 |
|
RU2736975C1 |
| BENZO[1,2,4]THIADIAZINE INHIBITORS OF HEPATITIS B VIRUS REPLICATION AND PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B | 2015 |
|
RU2574397C1 |
| HEPATITIS B VIRUS (HBV) INHIBITOR | 2019 |
|
RU2726456C1 |
| BISDIAZABICYCLO-COMPOUND FOR TREATMENT AND / OR PREVENTION OF DISEASES OR DISORDERS ASSOCIATED WITH THE HEPATITIS VIRUS | 2018 |
|
RU2749730C1 |
| HEPATITIS VIRUS PENETRATION INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEPATITIS | 2017 |
|
RU2662161C1 |
| COMPOSITION FOR TREATING HEPATITIS C AND METHOD OF TREATING HEPATITIS C | 2010 |
|
RU2447899C2 |
| METHOD OF TREATMENT OF PATIENTS WITH INFECTIONS INDUCED BY HEPATITIS B VIRUS | 1993 |
|
RU2157215C2 |
| ANTAGONISTS OF TOL-LIKE RECEPTOR 4 AND USE IN AUTOIMMUNE LIVER DISEASES | 2016 |
|
RU2707560C2 |
